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Abstract: During the experiment, the modeling of endothelial dysfunction of male rats was 
performed by intraperitoneal administration of L-NAME at a dose of 25 mg/kg for 7 days, and 
the same of female rats was performed by bilateral ovarioectomy and further intraperitoneal 
administration of L-NAME at a dose of 25 mg/kg for 7. The deficiency of nitric oxide as a 
result of the NO-synthase blockade was accompanied by the impairment of the endothelium-
dependent and independent vasodilatation estimated in the pharmacological tests, which was 
expressed in the increasing coefficient of endothelial dysfunction. As a result of the research it 
was discovered that the combined application of thioctic acid at a dose of 50 mg/kg/day with 
antioxidant features and rosuvastatin at a dose of 0.85 mg/kg/day, which is a lipid-lowering 
drug, has endothelioprotective effect on the models of L-NAME-induced and hypoestrogen-L-
NAME-induced deficiency of nitric oxide, which is expressed in prevalence of endothelium-
dependent relaxations of vessels and decreasing coefficient of endothelial dysfunction, as well 
as prevention of increase in nitric oxide production. 
Keywords: L-NAME, endothelial dysfunction, thioctic acid, rosuvastatin, nitric oxide, 
oxidative stress, ovarioectomy. 
 
Introduction: According to statistics, the 
incidence of and mortality from complications of 
cardiovascular diseases, particularly arterial 
hypertension (AH) and coronary heart disease (CHD) 
has been steadily increasing, which is evidence of the 
need to study the development mechanisms of this 
disease and possibilities of its correction capacity 
exposure to certain pathogenetic links [1]. The role of 
endothelial cells in the development of cardiovascular 
diseases was an important discovery for understanding 
the pathogenesis of hypertension, atherosclerosis, 
ischemic heart disease, cardiomyopathy, congestive 
heart failure, and metabolic disorders such as 
hyperlipidemia, hyperhomocysteinemia, diabetic 
vascular lesions, and venous transformation [2, 3, 4, 5]. 
This factor is called endothelial dysfunction (ED). 
The endothelium maintains homeostasis by 
regulating the balance of opposing processes: vascular 
tone, responsible for vasodilation and vasoconstriction; 
vascular anatomical structure, by regulating the 
synthesis and the inhibition of cell proliferation factors; 
hemostasis, by participating in the synthesis and the 
inhibition of fibrinolysis factors and platelet 
aggregation; and local inflammation, by producing pro- 
and anti-inflammatory cytokines [6, 7, 8, 9, 10]. The 
endothelium lines all vessels, regardless of their organ 
localization, therefore endothelial dysfunction, which is 
based on the decrease in nitric oxide (NO) synthesis by 
endothelial cells, is a predictor of both arterial and 
venous diseases, and diseases of the microvasculature 
components [11, 12, 13]. 
Therefore one of the main current tasks of 
pharmacology is the search for drugs and their 
combinations capable of correcting the endothelial 
dysfunction and having endothelioprotective effect.  
According to the literature, one of the 
chemical compounds having this effect is lipoic 
acid ([alpha]-LA) [14], which is a coenzyme in the 
oxidative decarboxylation of pyruvate acid to 
acetyl-CoA, and a-ketoglutaric acid to succinyl-
CoA (in Krebs cycle). Facilitating thus the 
conversion of lactic acid into pyruvic acid with 
further decarboxylation of the latter, [alpha]-LA 
promotes elimination of metabolic acidosis. 
All of the above reactions underlie the protective 
effect of dihydrolipoic acid, provide its therapeutic 
effect and cause a wide nosological range of use of the 
[alpha]-lipoic acid-based drugs [15, 16].  
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Main part: Subject to the above, the objective of 
this study was to investigate endothelioprotective 
properties of α-lipoic acid in the form of pellets 
Thioctacid BV (600 mg) at a dose of 50 mg/kg/day 
together with statin hypolipidemic drug Rosuvastatin 
(10 mg) at a dose of 0.85 mg/kg/day as one of the 
possible effective combinations used in case of 
endothelial dysfunction, with the help of models of  
L-NAME-induced and [17, 18, 19] hypoestrogen-L-
NAME-induced nitric oxide deficiency. 
Materials and research methods. Experiments 
were conducted in two animal models of endothelial 
dysfunction. The L-NAME-induced nitrogen deficiency 
was modeled in nonlinear white male rats weighing 
250-300 g, the NO-synthase inhibitor N-nitro-L-
arginine methyl ester (L-NAME, Sigma) was 
aministrated intraperitoneally once a day at a dose of  
25 mg/kg in the volume of 1 ml/kg for 7 days (n=10 
animals) [20, 21]. Intact animals were administered 
physiological NaCl solution in the same volume (n=10 
animals). Thioctic acid and rosuvastatin, as well as their 
combination were administered intragastrically daily in 
fasting state (gavage) at doses of 50 mg/kg/day and  
0.85 mg/kg/day, respectively, for 7 days.  
The hypoestrogen-L-NAME-induced nitrogen 
deficiency was modeled in white female Wistar rats 
weighing 200-250 g. To simulate the endothelial 
dysfunction, the 3.5-month-old rats were anesthetized 
with chloral hydrate (300 mg/kg) with further bilateral 
ovariectomy. On day 43 (6 weeks after surgery) the 
NO-synthase inhibitor N-nitro-L-arginine methyl ester 
(L-NAME, Sigma) was administrated intraperitoneally 
once a day at a dose of 25 mg/kg in the volume of  
1 ml/kg for 7 days (n=10 animals) [17, 18, 19]. Intact 
animals were administered physiological NaCl solution 
in the same volume (n=10 animals). Thioctic acid and 
rosuvastatin, as well as their combination were 
administered intragastrically daily in fasting state 
(gavage) at doses of 50 mg/kg/day and 0.85 mg/kg/day, 
respectively, for 7 days, simultaneously with L-NAME.  
In both methods of modeling the anestetized 
(chloral hydrate 300 mg/kg and zoletil 150 m/kg, 
intraperitoneally) animals were taken to the experiment 
on day 8 after administration of L-NAME and drugs 
both in monotherapy and in their combination and their 
blood pressure (BP) and BP reaction on endothelium-
dependent (acetylcholine at a dose of 40 mg/g) and 
endothelium-independent (nitroprusside in a dose of  
30 mg/kg) vasodilation were assessed by inserting a 
catheter in the carotid artery. Pharmacological agents 
were administered by bolus injection into the right 
femoral vein.  
The systolic blood pressure (SBP), diastolic 
blood pressure (DBP) and heart rate (HR) were 
recorded with the use of the TSD104A sensor and the 
MP150 hardware and software system (Biopac 
System, Inc., USA). 
The degree of endothelial dysfunction in 
experimental animal, as well as the degree of its 
correction with the studied medications was assessed by 
the estimated coefficient of endothelial dysfunction 
(EDC) [17, 18, 19, 22]. 
The level of total nitrite in rats serum was taken for 
a biochemical marker of endothelial dysfunction  
[15, 23]. Statistical processing of data involved 
calculation of the average value and standard deviation. 
Differences were considered significant at p<0.05. 
Results and discussion: Blood pressure in intact 
male rats: systolic (SBP) – 125.0±6.3 mm Hg., diastolic 
(DBP) – 82.0±5.8 mm Hg. Administration of  
NO-synthase blocker, an L-arginine analogue,  
L-NAME, led to severe arterial hypertension (AH) 
(SBP – 190.3±6.7, DBP – 145.0±3.9 mm Hg.) (Fig. 1).
 
Figure 1. The influence of the thioctic acid (50 mg/kg) and rosuvastatin (0.85 mg/kg) on the blood pressure by the modeling of 
L-NAME (intraperitoneal administration of L-NAME at a dose of 25 mg/kg for 7 days)-induced deficiency of nitric oxide 
Note: * –  p<0.05 – as compared to intact group 
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Blood pressure in intact female rats: systolic 
(SBP) – 128.1±6.0 mm Hg, diastolic (DBP) – 
95.7±4.0 mm Hg. Modeling of pathology with the 
use of NO-synthase blockade, L-NAME on the 
background of hypoestrogen-induced nitric oxide 
deficiency led to arterial hypertension (SBP – 
169.9±7.3, DBP – 123.2±7.5 mm Hg) (Fig. 2). Thus, 
both models showed a significant increase in blood 
pressure, which indicates the role of nitric oxide in 
the development of hypertension.  
 
Figure 2. The influence of the thioctic acid (50 mg/kg) and rosuvastatin (0.85 mg/kg) on the blood pressure by the modeling of 
hypoestrogen-L-NAME (intraperitoneal administration of L-NAME at a dose of 25 mg/kg for 7 days)-induced deficiency of nitric oxide.  
 
Note: * –  at p<0.05 as compared to intact animals; ** – at p<0.05 as compared to L-NAME 
 
The results of vascular tests for endothelium-
dependent (acetylcholine) and endothelium-independent 
(sodium nitroprusside) relaxation of blood vessels and 
increase in EDC from 1.1±0.1 in intact animals to 5.4 ± 
0.6 (p<0.05) in animals with L-NAME-induced 
nitrogen deficiency indicate the impaired relationship of 
vasoconstriction and vasodilation mechanisms of 
vascular tone regulation. The group with 
ovarioectomy+L-NAME showed increase in EDC from 
с 0.8±0.11 in intact animals up to 4.6±0.6 (р<0.05). 
The group of male rats, where only rosuvastatin 
was administered on the background of L-NAME 
administration, had EDC equal to 3.1±0.3 (p<0.05), 
while the group with administration of thioctic acid 
in addition to rosuvastatin had EDC equal to 1.9±0.2, 
which was significantly less than in L-NAME-
administered animals (p<0.05) (Fig. 3). 
 
Figure 3. The influence of the thioctic acid (50 mg/kg) and rosuvastatin (0.85 mg/kg) on the endothelial dysfunction 
coefficient by the modeling of L-NAME (intraperitoneal administration of L-NAME at a dose of 25 mg/kg for 7 days)-induced 
deficiency of nitric oxide. 
 
Note: *– at p<0.05 as compared to intact animals; **– at p<0.05 as compared to L-NAME 
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The group of rats with ovarioectomy, where only 
rosuvastatin was administered on the background of  
L-NAME NO-synthase inhibitor, had EDC equal to 
1.7±0.2 (p<0.05), while the group with administration 
of thioctic acid in addition to rosuvastatin had EDC 
equal to 1.4±0.3, which was less than in L-NAME-
administered animals (p<0.05) (Fig. 4). 
 
Figure 4. The influence of the thioctic acid (50 mg/kg) and rosuvastatin (0.85 mg/kg) on the endothelial dysfunction 
coefficient by the modeling of hypoestrogen-L-NAME (intraperitoneal administration of L-NAME at a dose of 25 mg/kg  
for 7 days)-induced deficiency of nitric oxide. 
 
Note: * – at p<0.05 as compared to intact animals; ** – at p<0.05 as compared to L-NAME 
 
At the same time, we have also noted the 
antihypertensive effect of these drugs both in 
monotherapy and in combined application in both 
models, which was expressed in the decreasing blood 
pressure, which was: SBP – 162.9±7.6 mm Hg,  
DBP – 135.1±5.2 mm Hg (p<0.05) in the group of 
animals with L-NAME-induced nitric oxide 
deficiency, and SBP – 135.5±2.9 mm Hg, DBP – 
97.6±7.1 mm Hg in a group of animals with 
hypoestrogen-L-NAME-induced nitrogen oxide 
deficiency, respectively (p<0.05). Thus, we can state 
that the studied drugs prevented the development of 
severe hypertension, and SBP and DBP values were 
significantly lower than the corresponding values in 
animals with endothelial dysfunction. However, the 
model of L-NAME-induced nitrogen oxide 
deficiency showed unreliable to each other 
differences of these parameters between the groups of 
animals treated with rosuvastatin and thioctic acid as 
monotherapy and in their combination (Fig. 1) 
Though, it was found that upon modeling of 
hypoestrogen-L-NAME -induced hypertension, a 
combined use of rosuvastatin 0.85 mg/kg and thioctic 
acid 50 mg/kg, as opposed to monotherapy, 
normalized blood pressure to the target values not 
significantly different from those of intact animals 
(Fig. 2). 
Investigations of biochemical markers in a series 
of experimental animals confirmed an increasing 
endothelioprotective activity of drugs under combined 
use of thioctic acid and rosuvastatin in both models, 
which was expressed in the increasing content of nitrite 
ions (NOx) (μmol) [15, 23]. It was found that 
rosuvastatin and thioctic acid applied as monotherapy in 
the model of L-NAME-induced nitrogen oxide 
deficiency increased the concentration of nitrite ions in 
the plasma of laboratory animals, but these differences 
were not statistically significant. Thus, the combined 
use of these drugs has allowed to achieve a significant 
increase in the content of nitrite ions (Fig. 5). 
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Figure 5. The influence of the thioctic acid (50 mg/kg) and rosuvastatin (0.85 mg/kg) on the concentration of nitric ions (NOx) 
in rat serum with the modeling of nitric deficiency by intraperitoneal administration of L-NAME at a dose of 25 mg/kg. 
 
Note: *– at p<0.05 as compared to L-NAME; **– at p<0.05 as compared to intact animals 
 
Upon modeling the hypoestrogen-L-NAME-
induced nitrogen oxide deficiency, the combined use 
of rosuvastatin 0.85 mg/kg with thioctic acid  
50 mg/kg increased the content of nitrite ions up to 
85 μmol. In this case, monotherapy with rosuvastatin 
0.85 mg/kg and thioctic acid 50 mg/kg also had a 
significant effect on the studied parameter, however, 
to a lesser extent (Fig. 6). 
 
Figure 6. The influence of the thioctic acid (50 mg/kg) and rosuvastatin (0.85 mg/kg) on the concentration of nitric ions (NOx) 
in rat serum by the modeling of hypoestrogen-L-NAME (intraperitoneal administration of L-NAME at a dose of 25 mg/kg for 
7 days)-induced deficiency of nitric oxide. 
 
Note: *– at p<0.05 as compared to L-NAME; **– at p<0.05 as compared to intact animals 
 
Conclusion: Models of L-NAME- and 
hypoestrogen-L-NAME-induced nitrogen oxide 
deficiency realize the antioxidant properties of thioctic 
acid, as according to the literature, inhibition of nitrogen 
oxide production upon L-NAME use is accompanied by 
a significant increase in the spontaneous production of a 
superoxide-anion radical [5, 16, 20]. Hyperproduction 
of a superoxide radical and its derivatives such as 
oxygen radicals is a mechanism of the development of 
oxidative stress (OS) resulting in suppression of 
 Molchanova O.V., Pokrovskaya T.G., Povetkin S.V., K.M. Reznikov Endothelioprotective property of the 
combination of the thioctic acid and rosuvastatin shown in the endothelial dysfunction models. Research 
result: pharmacology and clinical pharmacology. 2016. Vol. 2, №1 (2): P. 9-15 
14 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
antioxidant protection and increased formation of 
oxidation products, which is a factor for the formation 
of endothelial dysfunction [20, 21, 24]. At the same 
time this link in the pathogenesis of endothelial 
dysfunction is one of the application points for use of 
antioxidants as agents in addition to drugs with proven 
endothelioprotective effect, such as rosuvastatin, for ED 
correction [26, 27, 28]. As a result of the research it 
was found that the combined application of rosuvastatin 
at a dose of 0,85 mg/kg/day and thioctic acid at a dose 
of 50 mg/kg/day, had greater endothelioprotective effect 
on the L-NAME- and hypoestrogen-L-NAME-induced 
nitric oxide deficiency models as compared to 
monotherapy with rosuvastatin, which was expressed in 
the reduction of the coefficient of endothelial 
dysfunction (EDC) to a level close to that of intact 
animals, as well as in the prevention of reduced content 
of nitrite ions NOx. In addition, there was a significant 
prevention of hypertension development, that could not 
be achieved with rosuvastatin-based monotherapy, 
whereby narrow pathogenetic orientation of 
rosuvastatin on the background of endothelial 
dysfunction is associated with its pleiotropic effects, in 
particular, reduced level of proinflammatory cytokines - 
interleukin-6, which is associated with the development 
of endothelial dysfunction, whereas one of the reasons 
such as increased biodegradation of nitrogen oxide 
resulting from peroxidation remains uncompensated 
[25, 28, 29, 30]. Therefore, rosuvastatin-based 
monotherapy of endothelial dysfunction is considered 
insufficient, and causes further the search for more 
effective ways of pharmacotherapy, one of which is the 
combined use of rosuvastatin with thioctic acid. In our 
view, the combination of rosuvastatin with thioctic acid 
is justified not only for studying its endothelio- and 
cardioprotective effect associated with the prevention of 
indirect inhibition of NO-synthase by correction of 
oxidative stress, improvement of blood circulation and 
endoneural neurotrophism through the prevention of 
ischemic damage to the nervous tissue, acceleration of 
the pulse conduction along the nerve [16, 31], but also 
due to the possibility of justifying its use for leveling the 
side effects of statins associated with a reduction of one 
of the most important antioxidants – glutathione, since 
restoration of glutathione [32] through activation of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
is one of the most important properties of thioctic acid 
[26, 30, 33]. 
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